131 related articles for article (PubMed ID: 12585946)
1. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Fournier A; Oprisiu R; Andrejak M; Fernandez L; Achard JM
JAMA; 2003 Feb; 289(6):700; author reply 701. PubMed ID: 12585946
[No Abstract] [Full Text] [Related]
2. Losartan vs atenolol in prevention of stroke and cardiovascular disease.
Messerli FH; Grossman E; Fournier A
JAMA; 2003 Feb; 289(6):700-1; author reply 701. PubMed ID: 12585945
[No Abstract] [Full Text] [Related]
3. Effects of losartan in hypertension without vascular disease.
Messerli FH
Ann Intern Med; 2004 Apr; 140(7):W29. PubMed ID: 15069010
[No Abstract] [Full Text] [Related]
4. Pulse pressure and antihypertensive agents.
Safar ME; O'Rourke MF
Hypertension; 2005 Aug; 46(2):e6; author reply e6-7. PubMed ID: 16027242
[No Abstract] [Full Text] [Related]
5. [Left ventricular hypertrophy. Recent aspects of diagnosis and therapy].
Schmieder RE; Schneider MP
MMW Fortschr Med; 2002 Oct; 144(42):45-6. PubMed ID: 12533997
[No Abstract] [Full Text] [Related]
6. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Fuchs FD
Lancet; 2002 Jun; 359(9324):2203; author reply 2203-4. PubMed ID: 12091010
[No Abstract] [Full Text] [Related]
7. [Clinical hypertensiology: analysis of trials completed in 2001-2002].
Karpov IuA
Kardiologiia; 2002; 42(10):62-6. PubMed ID: 12494060
[No Abstract] [Full Text] [Related]
8. Summaries for patients. Benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.
Ann Intern Med; 2003 Aug; 139(3):I28. PubMed ID: 12899605
[No Abstract] [Full Text] [Related]
9. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
10. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
[TBL] [Abstract][Full Text] [Related]
11. The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study.
Olsen MH; Wachtell K; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Lyle PA; Nieminen MS
J Hum Hypertens; 2006 Jun; 20(6):460-4. PubMed ID: 16572193
[No Abstract] [Full Text] [Related]
12. The LIFE Trial in 2004.
Beevers DG
J Hum Hypertens; 2004 Jun; 18(6):365. PubMed ID: 15153931
[No Abstract] [Full Text] [Related]
13. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Ibsen H; Lindholm LH; Pedersen OL; Dahlöf B; Kjeldsen S
Ugeskr Laeger; 2003 Jan; 165(5):459-62. PubMed ID: 12599844
[TBL] [Abstract][Full Text] [Related]
14. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Baumgart P
MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
[No Abstract] [Full Text] [Related]
15. [When compliance doesn't work out. Calculate the risk of stroke for hypertensive patients!].
MMW Fortschr Med; 2004 Feb; 146(7):61. PubMed ID: 15347060
[No Abstract] [Full Text] [Related]
16. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
17. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
18. New strategies for prevention of ischemic stroke: the LIFE study.
Adams HP
Curr Neurol Neurosci Rep; 2003 Jan; 3(1):46-51. PubMed ID: 12507410
[TBL] [Abstract][Full Text] [Related]
19. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
Hamon M
Lancet; 2002 Jun; 359(9324):2199-200; author reply 2203-4. PubMed ID: 12091003
[No Abstract] [Full Text] [Related]
20. Diuretics in the LIFE study.
Kato J; Eto T
Lancet; 2004 Jul 31-Aug 6; 364(9432):413; author reply 413-4. PubMed ID: 15288732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
